The pathogenesis of NIDDM involves a defective expression of the GIP receptor

Diabetologia

Volumn 40, Issue 8, 1997, Pages 984-986

  Holst, J J ^a,d   Gromada, J ^b   Nauck, M A ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE;

GENE EXPRESSION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SHORT SURVEY;

DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GENE EXPRESSION REGULATION; HUMANS; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 0030876081     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050779     Document Type: Short Survey

References (34)

1. Pederson RA (1994) Gastric inhibitory polypeptide. In Walsh JH, Dockray GJ (eds) Gut peptides. Biochemistry and physiology. Raven Press New York, pp. 217-260
2. Holst JJ (1994) Glucagon-likepeptide-1 (GLP-1) - a newly discovered gastrointestinal hormone. Gastroenterology 107: 1848-1855
3. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 (7-36) amide infused at near-physiological insulinotropic and glucose concentrations. J Clin Endocrinol Metab 76: 912-917
4. Ørskov C (1992) Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia 35: 701-711
5. Habener JF (1993) The incretin notion and its relevance to diabetes. Endocrinol Metab Clin North Am 22: 775-794
6. Kolligs F, Fehmannn HC, Göke R, Göke B (1995) Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin (9-39) amide. Diabetes 44: 16-19
7. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei M, Bloom SR (1995) Glucagon-like peptide-1 is a physiological incretin in the rat. J Clin Invest 95: 417-421
8. Scrocchi L, Brown TJ, MacLusky N et al. (1996) Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Medicine 2: 1254-1258
9. Brown JC (1994) Enteroinsular axis. In: Walsh JH, Dockray GJ (eds) Gut peptides. Biochemistry and physiology. Raven Press New York, pp. 765-784
10. Tseng C-C, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM (1996) Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). J Clin Invest 11: 2440-2445
11. Tronier B, Dejgård A, Andersen T, Madsbad S (1985) Absence of incretin effect in obese type 2 and diminished effect in lean type 2 and obese subjects. Diab Res Clin Pract [Suppl. 1]:S568
12. Nauck M, Stöckmann R, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46-52
13. Nauck MA, Homberger E, Siegel EG et al. (1986) Incretin effect of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498
14. Vaag AA, Holst JJ, Vølund A, Beck-Nielsen H (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM) - evidence for decreased glucagon-like peptide-1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135: 435-432
15. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W (1996) Preserved incretin activity of glucagon-like peptide-1 (7-36 amide), but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307
16. Elahi D, McAloon-Dyke M, Fukagawa NK et al. (1994) The insulinotropic actions of glucose dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (7-37) in normal and diabetic subjects. Regul Pept 51: 63-74
17. Nauck M, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeld W (1993) Normalization of fasting hyperglycemia by exogenous GLP-1 in type-2 diabetic patients. Diabetologia 36: 741-744
18. Creutzfeldt W, Kleine N, Willms B, Ørskov C, Holst JJ, Nauck MA (1996) Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide-1 (7-36 amide) in type I diabetic patients. Diabetes Care 19: 580-586
19. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glucose reponses and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1 [7-36 amide]) in type 2 (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332
20. Fehmann H-C, Göke R, Göke B (1995) Cell and molecular biology of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin releasing polypeptide (GIP). Endocr Rev 16: 390-410
21. Krarup T, Saurbrey N, Moody AJ, Kühl C, Madsbad S (1987) Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. Metabolism 36: 677-681
22. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ (1995) Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131
23. Thorens B, Porret A, Bühler L, Deng SH, Morel P, Widmann C (1993) Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682
24. Gremlich S, Porret A, Hani EH et al. (1995) Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44: 1202-1208
25. Volz A, Göke R, Lankat-Buttgereit B, Fehmann HC, Bode HP, Göke B (1995) Molecular cloning, functional expression and signal transduction of the GIP receptor cloned from a human insulinoma. FEBS Lett 373: 23-29
26. Gromada J, Dissing S, Bokvist K et al (1995) Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting betaTC3 cells by enhancement of intracellular calcium mobilization. Diabetes 44: 767-774
27. Gromada J, Rorsman P, Dissing S, Wull B (1995) Stimulation of cloned human glucagon-like peptide 1 receptor expressed in HEK 293 cells induces cAMP-dependent activation of calcium-induced calcium release. FEBS Letts 373: 182-186
28. Ding W-G, Gromada J (1992) Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes 46: 615-621
29. Meneilly GS, Bryer-Ash M, Elahi D (1993) The effect of glyburide on β-cell sensitivity to glucose-dependent insulinotropic polypeptide. Diabetes Care 16: 110-114
30. Gutniak MK, Juntti-Berggren L, Hellström L, Guenifi A, Holst JJ, Efendic S (1996) GLP-1 (glucagon-like peptide-1) enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 19: 857-863
31. Jia X, Elliot R, Kwok YN, Pederson RA, McIntosh CHS (1995) Altered glucose dependence of glucagon-like peptide I (7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas. Diabetes 44: 495-500
32. Kubota A, Yamada Y, Hayami T et al. (1996) Identification of two missense mutations in the GIP receptor gene: A functional study and association analysis with NIDDM. Diabetes 45: 1701-1705
33. Kosaka K, Kuzuya T, Hagura R, Yoshinaga H (1996) Insulin response to oral glucose load consistently decreased in established NIDDM: the usefulness of decreased early insulin response as a predictor of NIDDM. Diabet Medicine 13:S109-S119
34. Holz GG, Kühtreiber WM, Habener JF (1993) Pancreatic beta-cells are rendered glucose competent by the insulinotropic hormones glucagon-like peptide-1(7-37). Nature 361: 362-365